Long-term Market Sustainability for Infused Biosimilars in the U.S.

36 Pages

This report assesses the current state and future sustainability of the U.S. biosimilars market. While biosimilars have generated significant savings, adoption remains inconsistent due to formulary design, rebate structures, provider incentives, and regulatory complexity. The analysis warns that continued pricing pressure could discourage competition and limit long-term savings. The report calls for policy and market reforms to support sustainable competition, predictable incentives, and broader patient access to biosimilars.

Join for free to read

Case Study Empowering Sustainable, Long-Term Growth

Ebook Measuring Security Awareness Impact for Long-Term Success

White Paper “Forever Risks” are Demanding the Attention of CFOs Today and…

More from IQVIA

Report Spotlight on Biosimilars: Sustainable Competition for Biologics

Report The Prospects for Biosimilars of Orphan Drugs in Europe

Ebook Practical Insights for Cell and Gene Therapy Long-term Follow-up…

Report

Long-term Market Sustainability for Infused Biosimilars in the U.S.

Long-term Market Sustainability for Infused Biosimilars in the U.S.

You Might Also Like

More from IQVIA